# EDGAR Filing Document

**Accession Number:** 0001783908
**File Stem:** 0001783908-26-000007
**Filing Date:** 2026-3
**Character Count:** 13785
**Document Hash:** 840f304a3516968607e3374aa43f9f4a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001783908-26-000007.hdr.sgml**: 20260302

**ACCESSION NUMBER**: 0001783908-26-000007

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260226

**FILED AS OF DATE**: 20260302

**DATE AS OF CHANGE**: 20260302

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Patil Neena M
- **CENTRAL INDEX KEY:** 0001783908

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33500
- **FILM NUMBER:** 26709166

**MAIL ADDRESS:**
- **STREET 1:** JAZZ PHARMACEUTICALS
- **STREET 2:** 3000 EL CAMINO REAL, 2 PALO ALTO SQUARE
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94306
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Jazz Pharmaceuticals plc
- **CENTRAL INDEX KEY:** 0001232524
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981032470
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** FIFTH FLOOR, WATERLOO EXCHANGE
- **STREET 2:** WATERLOO ROAD
- **CITY:** DUBLIN
- **PROVINCE COUNTRY:** L2
- **ZIP:** D04 E5W7
- **BUSINESS PHONE:** 353-1-634-7800

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** FIFTH FLOOR, WATERLOO EXCHANGE
- **STREET 2:** WATERLOO ROAD
- **CITY:** DUBLIN
- **PROVINCE COUNTRY:** L2
- **ZIP:** D04 E5W7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** JAZZ PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20030513

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Patil Neena M<br><sub>(Last) (First) (Middle)</sub><br>5TH FL, WATERLOO EXCHANGE<br>WATERLOO RD<br><sub>(Street)</sub><br>DUBLIN 4, L2 <br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-26 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_EVP & Chief Legal Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Jazz Pharmaceuticals plc [ JAZZ ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 2026-02-26 |  | M |  | 20125 | A | $113.1 | 73464 | D |  |
| Ordinary Shares | 2026-02-26 |  | S |  | 16602 | D | 192.5271<sup>(1)</sup> | 56862 | D |  |
| Ordinary Shares | 2026-02-26 |  | M |  | 875 | A | $113.1 | 57737 | D |  |
| Ordinary Shares | 2026-02-26 |  | S |  | 875 | D | 192.0651<sup>(2)</sup> | 56862 | D |  |
| Ordinary Shares | 2026-02-26 |  | M |  | 27084 | A | $137.12 | 83946 | D |  |
| Ordinary Shares | 2026-02-26 |  | S |  | 15555 | D | 190.2801<sup>(3)</sup> | 68391 | D |  |
| Ordinary Shares | 2026-02-26 |  | M |  | 2916 | A | $137.12 | 71307 | D |  |
| Ordinary Shares | 2026-02-26 |  | S |  | 2916 | D | 189.8117<sup>(4)</sup> | 68391 | D |  |
| Ordinary Shares | 2026-02-26 |  | A<sup>(5)</sup> |  | 10079 | A | $0.0 | 78470 | D |  |
| Ordinary Shares | 2026-02-26 |  | S |  | 11529 | D | 191.6455<sup>(6)</sup> | 66941 | D |  |
| Ordinary Shares | 2026-02-26 |  | S |  | 3523 | D | 193.5831<sup>(7)</sup> | 63418 | D |  |
| Ordinary Shares | 2026-02-26 |  | S |  | 1061 | D | 190.0035<sup>(8)</sup> | 62357 | D |  |
| Ordinary Shares | 2026-02-26 |  | S |  | 549 | D | 190.7963<sup>(9)</sup> | 61808 | D |  |
| Ordinary Shares | 2026-02-26 |  | S |  | 1784 | D | 191.8789<sup>(10)</sup> | 60024 | D |  |
| Ordinary Shares | 2026-02-26 |  | S |  | 1009 | D | 192.7915<sup>(11)</sup> | 59015 | D |  |
| Ordinary Shares | 2026-02-26 |  | S |  | 197 | D | 193.5982<sup>(12)</sup> | 58818 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Incentive Stock Option (right to buy) | $113.1 | 2026-02-26 |  | M |  |  | 875 | <sup>(13)</sup> | 2030-02-26 | Ordinary Shares | 875 | $0.0 | 0 | D |  |
| Incentive Stock Option (right to buy) | $137.12 | 2026-02-26 |  | M |  |  | 2916 | <sup>(14)</sup> | 2029-08-07 | Ordinary Shares | 2916 | $0.0 | 0 | D |  |
| Non-Qualified Stock Option (right to buy) | $113.1 | 2026-02-26 |  | M |  |  | 20125 | <sup>(13)</sup> | 2030-02-26 | Ordinary Shares | 20125 | $0.0 | 0 | D |  |
| Non-Qualified Stock Option (right to buy) | $137.12 | 2026-02-26 |  | M |  |  | 27084 | <sup>(14)</sup> | 2029-08-07 | Ordinary Shares | 27084 | $0.0 | 0 | D |  |

---

### Footnotes:

(1) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $192.1100 to $193.0100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

(2) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $192.0600 to $192.1100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

(3) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $189.9150 to $190.9000. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

(4) Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $189.7300 to $189.9150. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

(5) These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.

(6) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $191.3200 to $192.0600. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

(7) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $193.2900 to $193.8400. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

(8) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $189.395 to $190.3700. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

(9) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $190.4100 to $191.2150. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

(10) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $191.4750 to $192.4300. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

(11) Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $192.4600 to $193.4500. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

(12) Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $193.5300 to $193.6700. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

(13) These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.

(14) These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of July 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter.

**Signature:** By: /s/Paz Dizon, as attorney in fact For: Neena Patil  
**Date:** 2026-03-02

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**